Datasheet for ABIN2712518

Cortactin Protein (CTTN) (Transcript Variant 2) (Myc-DYKDDDDK Tag)

1 Image | 5 Publications

Go to Product page

Overview

Quantity:	20 µg
Target:	Cortactin (CTTN)
Protein Characteristics:	Transcript Variant 2
Origin:	Human
Source:	HEK-293 Cells
Protein Type:	Recombinant
Purification tag / Conjugate:	This Cortactin protein is labelled with Myc-DYKDDDDK Tag.
Application:	Antibody Production (AbP), Standard (STD)

Product Details

Characteristics:	• Recombinant human Cortactin (transcript variant 2) protein expressed in HEK293 cells. • Produced with end-sequenced ORF clone
Purity:	> 80 % as determined by SDS-PAGE and Coomassie blue staining

Target Details

Target:	Cortactin (CTTN)
Alternative Name:	Cortactin (CTTN Products)
Background:	This gene is overexpressed in breast cancer and squamous cell carcinomas of the head and neck. The encoded protein is localized in the cytoplasm and in areas of the cell-substratum contacts. This gene has two roles: (1) regulating the interactions between components of adherens-type junctions and (2) organizing the cytoskeleton and cell adhesion structures of

Target Details

	epithelia and carcinoma cells. During apoptosis, the encoded protein is degraded in a caspase-dependent manner. The aberrant regulation of this gene contributes to tumor cell invasion and metastasis. Three splice variants that encode different isoforms have been identified for this gene.
Molecular Weight:	57.3 kDa
NCBI Accession:	NP_612632
Pathways:	MAPK Signaling

Application Details

Application Notes:	Recombinant human proteins can be used for: Native antigens for optimized antibody production Positive controls in ELISA and other antibody assays
Comment:	The tag is located at the C-terminal.
Restrictions:	For Research Use only

Handling

Concentration:	50 µg/mL
Buffer:	25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10 % glycerol.
Storage:	-80 °C
Storage Comment:	Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.

Publications

Product cited in:	Cortés-Vicente, Gallardo, Martínez, Díaz-Manera, Querol, Rojas-García, Illa: "Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin." in: **JAMA neurology**, Vol. 73, Issue 9, pp. 1099-104, (2016) (PubMed). Labrador-Horrillo, Martínez, Selva-OCallaghan, Trallero-Araguás, Grau-Junyent, Vilardell-Tarrés, Juarez: "Identification of a novel myositis-associated antibody directed against cortactin." in: **Autoimmunity reviews**, Vol. 13, Issue 10, pp. 1008-12, (2014) (PubMed). Gallardo, Martínez-Hernández, Titulaer, Huijbers, Martínez, Ramos, Querol, Díaz-Manera, Rojas-

Publications

García, Hayworth, Verschuuren, Balice-Gordon, Dalmau, Illa: "Cortactin autoantibodies in myasthenia gravis." in: **Autoimmunity reviews**, Vol. 13, Issue 10, pp. 1003-7, (2014) (PubMed).

Wang, Henry, Distefano, Wang, Räikkönen, Mönkkönen, Tanaka, Morita: "Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human V?2V?2 T cells." in: **Journal of immunology (Baltimore, Md. : 1950)**, Vol. 191, Issue 3, pp. 1029-42, (2013) (PubMed).

Llanos, Royer, Lu, Bergamaschi, Lee, Lu: "Inhibitory member of the apoptosis-stimulating proteins of the p53 family (iASPP) interacts with protein phosphatase 1 via a noncanonical binding motif." in: **The Journal of biological chemistry**, Vol. 286, Issue 50, pp. 43039-44, (2011) (PubMed).

Images



Western Blotting

Image 1. Validation with Western Blot